TherapeuticsMD Inc (NASDAQ:TXMD) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Thursday.

According to Zacks, “TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida. “

Several other brokerages also recently commented on TXMD. Stifel Nicolaus reissued a “buy” rating and set a $20.00 target price on shares of TherapeuticsMD in a research note on Wednesday, May 24th. Oppenheimer Holdings, Inc. raised TherapeuticsMD from a “market perform” rating to an “outperform” rating and set a $10.00 target price for the company in a research note on Tuesday, July 11th. CIBC raised TherapeuticsMD from a “market perform” rating to an “outperform” rating in a research note on Tuesday, July 11th. Jefferies Group LLC set a $15.00 target price on TherapeuticsMD and gave the stock a “buy” rating in a research note on Wednesday, June 14th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $33.00 price target on shares of TherapeuticsMD in a report on Wednesday, May 10th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $18.00.

Shares of TherapeuticsMD (NASDAQ TXMD) traded down 14.1332% on Thursday, hitting $4.8343. 1,430,010 shares of the stock traded hands. TherapeuticsMD has a 1-year low of $3.50 and a 1-year high of $8.30. The stock has a 50 day moving average of $4.62 and a 200-day moving average of $5.62. The stock’s market cap is $985.84 million.

TRADEMARK VIOLATION WARNING: This report was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://www.watchlistnews.com/therapeuticsmd-inc-txmd-rating-lowered-to-sell-at-zacks-investment-research/1445076.html.

Several hedge funds have recently added to or reduced their stakes in the company. Sphera Funds Management LTD. purchased a new stake in TherapeuticsMD during the first quarter valued at $4,176,000. Vanguard Group Inc. boosted its stake in TherapeuticsMD by 5.6% in the first quarter. Vanguard Group Inc. now owns 9,801,870 shares of the company’s stock valued at $70,574,000 after buying an additional 515,992 shares during the period. JPMorgan Chase & Co. boosted its stake in TherapeuticsMD by 2.5% in the first quarter. JPMorgan Chase & Co. now owns 13,725,853 shares of the company’s stock valued at $98,827,000 after buying an additional 329,245 shares during the period. State Street Corp boosted its stake in TherapeuticsMD by 6.9% in the first quarter. State Street Corp now owns 3,903,491 shares of the company’s stock valued at $28,105,000 after buying an additional 253,237 shares during the period. Finally, Stifel Financial Corp boosted its stake in TherapeuticsMD by 125.4% in the first quarter. Stifel Financial Corp now owns 429,362 shares of the company’s stock valued at $3,091,000 after buying an additional 238,885 shares during the period.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Get a free copy of the Zacks research report on TherapeuticsMD (TXMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.